Fresenius SE & Co. (OTCMKTS:FSNUY) Reaches New 52-Week High – Time to Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $14.75 and last traded at $14.55, with a volume of 80762 shares. The stock had previously closed at $14.13.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

The firm has a 50 day moving average of $13.83 and a two-hundred day moving average of $12.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.31 and a quick ratio of 1.00. The stock has a market cap of $32.50 billion, a PE ratio of 27.45 and a beta of 0.83.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. The company had revenue of $6.48 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Fresenius SE & Co. had a net margin of 5.09% and a return on equity of 9.33%. Research analysts predict that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.